ribosomal protein S4X pseudogene 17Genealiases: []
Q-omics provides the consensus-scored RPS4XP17 profile across patient tissues and cancer cell-line models. RPS4XP17 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS4XP17 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, RPS4XP17 RNA expression shows 15,283 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where RPS4XP17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS4XP17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS4XP17 survival associations across molecular data types. RPS4XP17 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS4XP17 RNA expression–survival associations across cancer types. High RPS4XP17 expression shows unfavorable associations in ACC, LUAD, SARC, OV and KICH, but favorable associations in READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS4XP17 RNA expression.
This table summarizes RPS4XP17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS4XP17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS4XP17 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, LIHC, CHOL and LUAD. The COAD box plot shows higher RPS4XP17 RNA expression in tumor versus normal tissue (log2 FC = +0.921, t-test p < 0.001).
This table shows molecular features associated with RPS4XP17 in patient tissues and cancer cell lines. In patient samples, RPS4XP17 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
